Schöffski P - Search Results

1

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.

Benjamin RS, Schöffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J, Schuetze S, Blay JY, Reichardt P, Rosen LS, Skubitz K, McCoy S, Sun YN, Stepan DE, Baker L. Benjamin RS, et al. Among authors: schoffski p. Cancer Chemother Pharmacol. 2011 Jul;68(1):69-77. doi: 10.1007/s00280-010-1431-9. Epub 2010 Sep 14. Cancer Chemother Pharmacol. 2011. PMID: 20838998 Free PMC article. Clinical Trial.

2

Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer.

Bokemeyer C, Oechsle K, Hartmann JT, Schöffski P, Schleucher N, Metzner B, Schleicher J, Kanz L. Bokemeyer C, et al. Among authors: schoffski p. Br J Cancer. 2002 Nov 4;87(10):1066-71. doi: 10.1038/sj.bjc.6600629. Br J Cancer. 2002. PMID: 12402143 Free PMC article.

3

A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.

Planting A, van der Gaast A, Schöffski P, Bartkowski M, Verheij C, Noe D, Ferrante K, Verweij J. Planting A, et al. Among authors: schoffski p. Cancer Chemother Pharmacol. 2005 Feb;55(2):136-42. doi: 10.1007/s00280-004-0905-z. Epub 2004 Sep 29. Cancer Chemother Pharmacol. 2005. PMID: 15592721 Clinical Trial.

4

Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors.

Hartmann JT, Rick O, Oechsle K, Kuczyk M, Gauler T, Schöffski P, Schleicher J, Mayer F, Teichmann R, Kanz L, Bokemeyer C. Hartmann JT, et al. Among authors: schoffski p. Ann Surg. 2005 Aug;242(2):260-6. doi: 10.1097/01.sla.0000171303.32006.a2. Ann Surg. 2005. PMID: 16041217 Free PMC article.

5

Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines.

Prenen H, Guetens G, de Boeck G, Debiec-Rychter M, Manley P, Schoffski P, van Oosterom AT, de Bruijn E. Prenen H, et al. Among authors: schoffski p. Pharmacology. 2006;77(1):11-6. doi: 10.1159/000091943. Epub 2006 Mar 8. Pharmacology. 2006. PMID: 16534250

6

Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography.

Prenen H, Deroose C, Vermaelen P, Sciot R, Debiec-Rychter M, Stroobants S, Mortelmans L, Schöffski P, Van Oosterom A. Prenen H, et al. Among authors: schoffski p. Anticancer Res. 2006 Mar-Apr;26(2A):1247-52. Anticancer Res. 2006. PMID: 16619531 Free article.

7

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M. Prenen H, et al. Among authors: schoffski p. Clin Cancer Res. 2006 Apr 15;12(8):2622-7. doi: 10.1158/1078-0432.CCR-05-2275. Clin Cancer Res. 2006. PMID: 16638875

8

Simultaneous determination of AMN107 and Imatinib (Gleevec, Glivec, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection.

Guetens G, Prenen H, De Boeck G, van Oosterom A, Schöffski P, Highley M, de Bruijn EA. Guetens G, et al. Among authors: schoffski p. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 1;846(1-2):341-5. doi: 10.1016/j.jchromb.2006.08.004. Epub 2006 Sep 7. J Chromatogr B Analyt Technol Biomed Life Sci. 2007. PMID: 16962394

9

Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.

Reichardt P, Nielsen OS, Bauer S, Hartmann JT, Schöffski P, Christensen TB, Pink D, Daugaard S, Marreaud S, Van Glabbeke M, Blay JY; EORTC Soft Tissue and Bone Sarcoma Group. Reichardt P, et al. Among authors: schoffski p. Eur J Cancer. 2007 Apr;43(6):1017-22. doi: 10.1016/j.ejca.2007.01.014. Epub 2007 Mar 1. Eur J Cancer. 2007. PMID: 17336054 Clinical Trial.

10

Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial.

Prenen H, Dumez H, Stefan C, Hoeben A, Wouters C, Van Lierde MA, Sciot R, van Oosterom AT, Peeters M, Polus M, Duck L, Gil T, Schöffski P. Prenen H, et al. Among authors: schoffski p. Acta Gastroenterol Belg. 2006 Oct-Dec;69(4):367-71. Acta Gastroenterol Belg. 2006. PMID: 17343077 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

400 results

Search Page